ML226
CAS No. 2055172-43-3
ML226( ML-226 )
Catalog No. M23918 CAS No. 2055172-43-3
ML226 is a α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor that inhibits ABHD11 in vitro and in situ.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 491 | In Stock |
|
| 10MG | 708 | In Stock |
|
| 25MG | 1071 | In Stock |
|
| 50MG | 1467 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameML226
-
NoteResearch use only, not for human use.
-
Brief DescriptionML226 is a α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor that inhibits ABHD11 in vitro and in situ.
-
DescriptionML226 is a α/β hydrolase domain-containing protein 11 (ABHD11) inhibitor that inhibits ABHD11 in vitro and in situ.
-
In Vitro——
-
In Vivo——
-
SynonymsML-226
-
PathwayOthers
-
TargetOther Targets
-
RecptorABHD11
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2055172-43-3
-
Formula Weight390.49
-
Molecular FormulaC23H26N4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESCCC1CCCCN1C(=O)N2N=CC(=N2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Isosorbide dinitrate
A vasodilator used in the treatment of Angina pectoris. Its actions are similar to nitroglycerin but with a slower onset of action.
-
6,7,4'-Trihydroxyfla...
6,7,4'-Trihydroxyflavanone possesses various pharmacological activities, including anti-rheumatic, anti-ischemic, anti-inflammatory, anti-osteoclastogenic, and protective effects against METH-induced deactivation of T cells. 6,7,4'-Trihydroxyflavanone can be used for studies about the treatment of METH-addicts suffering from neurodegenerative diseases.
-
FEN1 Inhibitor C2
FEN1-IN-4 is an inhibitor of human flap endonuclease-1 (hFEN1)FEN1 Inhibitor C2 inhibition selectively impairs proliferation of colon cancer cells deficient in Cdc4 and Mre11a, both frequently mutated in colorectal cancers.?
Cart
sales@molnova.com